ACT-001 is under clinical development by Accendatech and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ACT-001’s likelihood of approval (LoA) and phase transition for Glioblastoma Multiforme (GBM) took place on 25 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ACT-001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ACT-001 overview

ACT-001 is under development for the treatment of progressing fibrosing interstitial lung disease and idiopathic pulmonary fibrosis, glioblastoma multiforme, pediatric diffuse intrinsic pontine glioma and recurrent optic neuromyelitis lineage-associated optic neuritis. It is administered orally. The drug candidate is dimethylaminomicheliolide (DMAMCL), a micheliolide (MCL) derivative. It was also under development for refractory acute myeloid leukemia. It acts by targeting STAT3, NFKB , PAI-1 and PKM2.

It was also under development for the treatment of solid tumors including colorectal cancer, primary non-small cell lung carcinoma, breast cancer, head and neck cancer, urogenital cancer, hepatocellular carcinoma, malignant melanoma,

Quick View ACT-001 LOA Data

Report Segments
  • Innovator
Drug Name
  • ACT-001
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.